News | May 14, 2019

PRINCIPIA BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN SANOFI’S PHASE 2B TRIAL OF SAR442168 IN MULTIPLE SCLEROSIS, TRIGGERING $30 MILLION MILESTONE SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage...

News | April 18, 2019

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH A MESOTHELIN-TARGETING T CELL ENGAGER (HPN536) IN PHASE 1/2A CLINICAL TRIAL FOR OVARIAN AND OTHER SOLID TUMOR CANCERS HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial...
leo. quis, elit. pulvinar tempus neque. Donec eleifend sem, Praesent quis